Caution should be taken with those that have megaloblastic anemia as B12 can reduce potassium levels in the blood
A 2016 paper, Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review (Girous et al., 2016), revealed that foods rich in nutrients stimulate GLP-1 more effectively
A single result may be noisy
While transdermal patch technology has advanced, injectable GLP-1 agonists remain the clinical gold standard because they achieve therapeutic blood levels that patches cannot consistently match
There are several phase 3 trials evaluating GLP-1s for indications, such as metabolic dysfunction-associated steatohepatitis (MASH), prediabetes, Alzheimer's disease, diabetic retinopathy, and osteoarthritis of the knee (in patients with obesity)